Franklin FTSE South Korea ETF vs Merck & Co., Inc. — how do they compare? Franklin FTSE South Korea ETF trades at $58.36 (market cap $1.83B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 192× Franklin FTSE South Korea ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Franklin FTSE South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 16 Days and Merck & Co., Inc. for 98 Days on average.
| FLKR | MRK | |
|---|---|---|
Market Cap | $1.83B | $351.28B |
Volume | 679,902 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $156.43 |
52-Week Low | $27.09 | $82.49 |
Typical Hold Time | 16 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →